Laurent Mortier

机构：Centre National de la Recherche Scientifique, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille’s Cardiology Hospital, Center for Infection and Immunity of Lille, Centre de Recherche en Cancérologie de Lyon, Hôpital Claude Huriez, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers · ORCID：0000-0002-2644-1790

发表论文 765 篇 · 总被引 36002 次 · h-index 63

代表论文

Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT). (2025 · Journal of Clinical Oncology · 被引 17)
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study (2025 · The Lancet Oncology · 被引 12)
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma (2025 · Annals of Oncology · 被引 8)
LBA53 IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary phase III results (IOB-013/KN-D18) (2025 · Annals of Oncology · 被引 6)
Long-Term Outcome of Colonic and Ileal Crohn’s Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease (2025 · Inflammatory Bowel Diseases · 被引 2)
Comparison of the tolerability and safety of hedgehog inhibitors in real-life: A cohort of 330 patients with locally advanced basal cell carcinoma. (2025 · Journal of Clinical Oncology · 被引 2)